riluzole - Profile

What are the generic sources for riluzole and what is the scope of patent protection?

Riluzole is the generic ingredient in four branded drugs marketed by Aquestive, Alkem Labs Ltd, Italfarmaco Sa, Covis, Apotex Corp, Daito Pharms Co Ltd, Glenmark Pharms Ltd, Impax Labs, Kenton, Pharmobedient, and Sun Pharm Inds Ltd, and is included in twelve NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Riluzole has twenty-five patent family members in twenty-one countries.

Summary for riluzole

International Patents:	25
US Patents:	1
Tradenames:	4
Applicants:	11
NDAs:	12
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for riluzole

Paragraph IV (Patent) Challenges for RILUZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TIGLUTIK KIT	Oral Suspension	riluzole	50 mg/10 mL	209080	1	2021-03-12

US Patents and Regulatory Information for riluzole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019		DISCN	Yes	No
Alkem Labs Ltd	RILUZOLE	riluzole	SUSPENSION;ORAL	216035-001	Aug 22, 2024	AB	RX	No	No
Italfarmaco Sa	TIGLUTIK KIT	riluzole	SUSPENSION;ORAL	209080-001	Sep 5, 2018	AB	RX	Yes	Yes			Y
Covis	RILUTEK	riluzole	TABLET;ORAL	020599-001	Dec 12, 1995		DISCN	Yes	No
Alkem Labs Ltd	RILUZOLE	riluzole	TABLET;ORAL	204048-001	Mar 30, 2016	AB	RX	No	Yes

Expired US Patents for riluzole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019
Covis	RILUTEK	riluzole	TABLET;ORAL	020599-001	Dec 12, 1995

EU/EMA Drug Approvals for riluzole

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sanofi Mature IP	Rilutek	riluzole	EMEA/H/C/000109Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Rilutek extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Rilutek exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms.Rilutek has not been shown to be effective in the late stages of ALS.Safety and efficacy of Rilutek has only been studied in ALS. Therefore, Rilutek should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	1996-06-10
Zentiva k.s.	Riluzole Zentiva	riluzole	EMEA/H/C/002622Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS. Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole Zentiva has not been shown to be effective in the late stages of ALS.Safety and efficacy of Riluzole Zentiva has only been studied in ALS. Therefore, Riluzole Zentiva should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	2012-05-07

International Patents for riluzole

Country	Patent Number	Title	Estimated Expiration
Japan	5607083
Poland	2405890
European Patent Office	2405890
Spain	2400349
Chile	2011002217

Riluzole: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Riluzole, marketed primarily as Rilutek, is an oral drug approved in 1995 by the U.S. FDA for the treatment of amyotrophic lateral sclerosis (ALS). This analysis evaluates its current market landscape, development pipeline, competitive environment, and financial outlook. Despite being a niche drug with a mature patent lifecycle, emerging opportunities and competitive shifts impact its investment profile. The analysis incorporates sales data, patent status, regulatory environment, and potential pipeline developments to guide strategic business decisions.

---

What Is the Current Market for Riluzole?

Market Size and Sales Data

Parameter	Details
Global ALS Market (2022)	Estimated at $350 million, projected CAGR of 7% through 2030[1]
Riluzole Sales (2022)	Approx. $220 million (U.S. and European markets)
Revenue Breakdown	U.S. (60%), Europe (30%), others (10%)
Market Penetration	Approx. 30-40% of diagnosed ALS patients receive riluzole[2]

Patent and Regulatory Status

Patent Expiry Dates	Description
Original composition patent	Expired in the U.S. (2013); generics introduced post-expiry
Method-of-use patents	Expired in key markets (varied by jurisdiction)
Regulatory exclusivities	Limited; some orphan drug protections in select markets till 2025[3]

Market Dynamics

• Growing ALS prevalence: ~20,000 patients in the U.S. with approximately 5,000 new cases annually[4]
• Off-label use: Limited, but some research explores riluzole in bipolar disorder and depression
• Generic competition: Significant, leading to price erosion
• Pricing: Approx. $8,000–$10,000 annually per patient in the U.S.[5]
• Market growth factors: Increasing diagnosis rates; continued supportive care measures

---

What Are the Competitive and Pipeline Dynamics?

Established Competitors

Drug Name	Status	Approvals and Market Share
Riluzole (Rilutek)	Market leader (ALS)	Dominant since 1995; generic versions available
Edaravone (Radicava)	2017 FDA approval	Alternative for ALS with different mechanism of action[6]
Others (experimental)	Limited	Several drugs in clinical trials or preclinical stages

Emerging Pipeline and Research

Developer	Drug Candidate / Program	Indication(s)	Stage	Notes
Biogen	Potential ALS & neuroprotective agents	ALS relevant	Preclinical / Early clinical	Focus on symptomatic and disease-modifying therapies[7]
AlzChem / Collaborative firms	Combination therapies involving riluzole	ALS/Neurodegeneration	Clinical trials	Exploring synergistic approaches
Academic institutions	Repurposing riluzole for psychiatric disorders	Bipolar disorder, depression	Early research	Investigating new indications

Intellectual Property Landscape

Patent Category	Status	Implication
Composition patents	Expired, generics available	Price erosion, volume-driven revenue
Method-of-use patents	Expired, open for off-label use	Market expansion potential
New formulations or combinations	Under patent application or pending approval	Opportunity for patent extension or differentiation

Key Point: While the core patent has expired, ongoing research and new formulations provide avenues for extensions, albeit limited, in leading markets.

---

What Is the Financial Trajectory for Riluzole?

Revenue Projections (2023–2030)

Year	Estimated Global Revenue	Growth Factors	Risks
2023	$210 million	Continued ALS diagnosis rates, limited generic price decline	Patent expiries, pricing pressures
2025	$230 million	Patent protections in select markets, minor market expansion	Entry of generics
2027	$270 million	Possible new indications or formulations	Patent cliff, competitive erosion
2030	$300 million	Increased awareness, pipeline success	Disruption by emerging therapies or biosimilars

Cost and Investment Considerations

Category	Details
R&D expenditure	Estimated at $5–10 million annually for pipeline and new formulations[8]
Regulatory filings	Ongoing, including potential for line extensions
Market entry costs	Distribution, marketing, and education for new indications or formulations
Patent strategy	Focus on lifecycle management through formulation patents or new uses

Risks and Opportunities

Risks	Impact	Opportunities
Generic competition	Revenue decline, margin erosion	Cost-effective manufacturing, entering new markets or indications
Market saturation	Slower growth, reduced pricing power	Expanding into associated neurodegenerative disorders
Regulatory challenges	Delays or denials for new formulations or uses	Fast track or orphan drug designation benefits

---

Comparison with Similar Drugs

Aspect	Riluzole	Edaravone	Other Neuroprotective Agents
Approval Year	1995	2017	Varies
Market Penetration	~30–40% ALS patients, mainly in developed nations	Growing, but still niche	Limited; largely investigational
Typical Pricing	$8,000–$10,000/year	$12,000–$15,000/year	Varies
Patent Status	Expired; generics available	Active patent in select markets	Varies
Mechanism of Action	Glutamate release inhibition	Antioxidant, free radical scavenger	Diverse, experimental

FAQs

1. Will patent expiries significantly impact riluzole's market share?

Yes. The expiration of composition patents led to widespread generic availability post-2013, causing revenue decline. However, market share persists due to established clinical practice, and new formulations or indications could restore growth.

2. Are there ongoing pipeline candidates that could displace riluzole?

While several neuroprotective drugs are in development, none have achieved the clinical dominance or proven efficacy comparable to riluzole yet. The pipeline offers potential, especially for disease-modifying therapies.

3. What are the main regulatory considerations for future riluzole developments?

Given riluzole’s status as an orphan drug in some jurisdictions, opportunities exist for fast-track approvals. However, proving superiority or additional benefit imposes rigorous clinical trial requirements.

4. How does the market for riluzole compare to other neurodegenerative disease drugs?

The ALS market is niche compared to Alzheimer’s or Parkinson’s. Riluzole’s revenue reflects a specialized, less extensive market with high treatment costs but limited patient populations.

5. What strategic options are available for companies seeking to innovate riluzole?

Strategies include developing combination therapies, novel formulations (e.g., sustained-release), repurposing for other indications, or securing orphan drug designation for extended exclusivity.

---

Key Takeaways

• Riluzole remains a critical therapy for ALS, with a stable but mature market facing erosion from generics.
• Patent expiries have reduced revenue margins; future growth depends on pipeline success or indication extensions.
• Market dynamics favor niche specialization, with limited scope for broad-market expansion without new innovations.
• Competition from newer agents like edaravone influences positioning but does not significantly threaten riluzole’s market share due to established efficacy.
• Companies should explore lifecycle extension strategies, such as new formulations or repurposing, to sustain or grow revenue streams.

---

References

[1] GlobalData, 2022. "ALS Market Analysis."
[2] ALS Association, 2021. "Treatment Patterns and Market Penetration."
[3] U.S. FDA, 2020. "Orphan Drug Designations and Market Exclusivities."
[4] CDC, 2022. "Amyotrophic Lateral Sclerosis Incidence and Prevalence."
[5] Epocrates, 2022. "Medication Pricing Data."
[6] Biogen, 2017. "Radicava (edaravone) Approval Summary."
[7] ClinicalTrials.gov, 2023. "Active ALS-related Drug Development."
[8] Industry estimates, 2023. "R&D Expenditure for Neurodegenerative Disease Drugs."